A review outlines how immune responses might guide more precise ALS treatments
Original source
Bridging the gap: neuroinflammation and the dawn of precision medicine in amyotrophic lateral sclerosis. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Study type
- Review
- Studied in
- Human, Animal
A review argues that inflammation in amyotrophic lateral sclerosis (ALS) can have different effects depending on disease stage and genetic background. It proposes identifying these immune patterns with biomarkers and matching treatments to them, rather than using broad immune suppression. The proposed approach still needs prospective validation in biomarker-defined groups.
Why this matters
If validated, this framework could help researchers develop ALS treatments aimed at specific inflammatory mechanisms and patient subgroups. It does not yet change treatment, because the proposed immune subtypes and treatment strategies have not been confirmed in prospective clinical studies.
Limitations and context
This is a review, not a new clinical trial. The proposed neuroimmune subtypes remain a working hypothesis, and the review says they need validation in biomarker-stratified cohorts. It does not establish that any precision immunotherapy is effective for people with ALS.